Managing Symptoms in the Pharmacy in the Pharmacy
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
B114. Rubefacients 2.1.Pdf
Bulletin 114 | October 2015 Community Interest Company Rubefacients for the treatment of soft-tissue disorders and topical pain relief (DROP-List) This is one of a number of bulletins providing further information on medicines contained in the PrescQIPP DROP-List (Drugs to Review for Optimised Prescribing).1 This bulletin focuses on rubefacients for the treatment of soft-tissue disorders and topical pain relief and provides the rationale for discontinuing supply on NHS FP10 prescriptions. It does not cover the prescribing of rubefacients for relieving muscle pain associated with methadone withdrawal or the prescribing of topical non-steroidal anti-inflammatory drugs (NSAIDs) or capsaicin cream. Further bulletins, including the DROP-List, are available on the PrescQIPP website: www.prescqipp.info Recommendations • All patients prescribed rubefacients should have their therapy reviewed. • Discontinue the prescribing of rubefacients on FP10. • Consider recommending or prescribing an effective alternative treatment if appropriate. • If these patients still wish to use a rubefacient they should be advised that they can be purchased as self-care over-the-counter (OTC) with the support of the community pharmacist. • Do not initiate new prescriptions for rubefacients. Background The PrescQIPP DROP-List is a list of medicines regarded as low priority for prescribing, poor value for money or medicines for which there are safer alternatives. There are also medicines which could be considered for self-care with the support of the community pharmacist included on the DROP-List. Some National Institute for Health and Care Excellence (NICE) do not do recommendations have also been included.1 Rubefacients features on the DROP-List as an item which has limited clinical value, has a NICE do not do recommendation associated with it and is suitable for self-care and should be purchased over- the-counter (OTC) if a patient wishes to use them. -
Astounding Cayenne
Astounding Cayenne W ANOTHER HERBAL HEALER SENT US BY THE GOD OF HEAVEN M 1 PART ONE OF TWO 5 8 7 ALSO IN THIS ISSUE: GOLDENSEAL / ECHINACEA What it is—Cayenne pepper belongs to the rhage. (Use it with an infusion with birthroot or star capsicum family, and its botanical name is capsi- root.) cum annuum. It is the red chili pepper that is used Cayenne pepper (or cayanne pepper as it’s to add flavor in food and has high medicinal val- sometimes spelled as) increases metabolism by ues. Cayenne contains vitamin E, vitamin C, vita- immediately speeding up the flow of blood in min K, carotenoids, and the complete B complex the arteries and veins. vitamins. It is also a source of organic calcium, po- This herb is a great food for the circulatory tassium, manganese, and dietary fiber. system. It feeds the necessary elements into the cell For health and medicinal purposes, you only structure of the arteries, veins, and capillaries; need to drink small amounts of cayenne powder, so that these regain the elasticity of youth again, mixed in a glass of water. and the blood pressure adjusts itself to normal. How cayenne can help you—Cayenne pep- It improves blood circulation. When any body per increases blood circulation. It also draws the part is sick, the blood flow to that area is usually blood to where it is especially needed. Because of affected. Cayenne helps to remove entire blood con- these special abilities, it can be used to help you in gestion, stimulates the blood flow, makes sure that many ways. -
Fast Facts Core Curriculum Wounds and Oral Care
Fast Facts Core Curriculum Wounds and Oral Care #37 Pruritus . .2-3 #40 Pressure Ulcer Management: Staging and Prevention . 4-5 #41 Pressure Ulcers: Debridement and Dressings . .6-7 #46 Malignant Wounds . 8-9 #121 Oral Mucositis: Diagnosis and Assessment . .10-11 #130 Oral Mucositis: Prevention and Treatment . 12-13 #147 Oropharyngeal Candidiasis . 14-15 #182 Xerostomia . 16-17 #218 Managing Wound Odor . 18-20 #249 Topical Nonsteroidal Anti-Inflammatory Drugs . 21-22 #250 Tracheostomy Care . .23-25 #281 Care of the Post-Laryngectomy Stoma . .26-28 1 #327 Topical Treatments for Acute and Chronic Wound Pain . .29-31 2 ! FAST FACTS AND CONCEPTS #37 PRURITUS Charles von Gunten MD and Frank Ferris MD Background Pruritus (itching) is a common and often distressing symptom near the end of life. The itch sensation may arise from stimulation of the skin itch receptor via unmyelinated C fibers, or itch may arise as a central phenomenon without skin involvement (e.g. opioid induced pruritus). Although histamine causes pruritus, many patients with pruritis show no signs of histamine release. Besides histamine, serotonin, prostaglandins, kinins, proteases and physical stimuli have all been implicated as mediators of pruritus. Common Causes • Dermatological (dryness, wetness, irritation, eczema, psoriasis) • Metabolic (hepatic failure, renal failure, hypothyroidism) • Hematologic (iron deficiency, polycythemia, thrombocytosis, leukemia, lymphoma) • Drugs (opioids, aspirin, drug reactions) • Infectious (scabies, lice, candida) • Allergy (urticaria, contact dermatitis, drug reactions) • Psychogenic Management Management of pruritus involves eliminating the cause when possible. Symptomatic strategies include: • Moisturizers: Dryness (xerosis) is very common and may exacerbate other causes. The mainstay of treatment is skin hydration. -
Marketing of Indian Spices As a Challenge in India Sajith Mohan1, Sheena
International Journal of Business and Management Invention ISSN (Online): 2319 – 8028, ISSN (Print): 2319 – 801X www.ijbmi.org Volume 2 Issue 2 ǁ February. 2013ǁ PP.26-31 Marketing of Indian Spices as a challenge in India Sajith Mohan1, Sheena. S.Rajan1, Unnikrishnan.G2 Dept of Business Management Studies, Annamalai university, Tamil Nadu. ABSTRACT: Spices are the pearls of developing countries. Spices are demand in the industrialized world, the export of these basic agricultural commodities by India can be relied upon to earn valuable foreign exchange. India, blessed with agro-climatic zones, exports spices to 120 countries. At present, production is around 3.2 million tones of different spices valued at approximately 4 billion US $, and holds a prominent position in world spice production. Her biggest trading partners are the US, Europe and Japan. India has the status of mere a commodity exporter in these markets, except for spice oils and oleoresins. Out of the 109 spices listed by the ISO, India produces as many as 75 in its various agro climatic regions. India accounts for about 45% (2, 50,000 tons) of the global spice exports, though exports constitute only some 8% of the estimated annual production .Over all, spices are grown in some 2.9 million hectares in the country. Spice production in India, as much of the agriculture in the country, is undertaken in millions of tiny holdings and determine the livelihood of large number of the rural population. The main challenge is for pepper, cardamom, coriander, ginger and turmeric. Among these spices pepper is facing major challenge in exporting in India. -
Pharmaceutical Compoundingand Dispensing, Second
Pharmaceutical Compounding and Dispensing Pharmaceutical Compounding and Dispensing SECOND EDITION John F Marriott BSc, PhD, MRPharmS, FHEA Professor of Clinical Pharmacy Aston University School of Pharmacy, UK Keith A Wilson BSc, PhD, FRPharmS Head of School Aston University School of Pharmacy, UK Christopher A Langley BSc, PhD, MRPharmS, MRSC, FHEA Senior Lecturer in Pharmacy Practice Aston University School of Pharmacy, UK Dawn Belcher BPharm, MRPharmS, FHEA Teaching Fellow, Pharmacy Practice Aston University School of Pharmacy, UK Published by the Pharmaceutical Press 1 Lambeth High Street, London SE1 7JN, UK 1559 St Paul Avenue, Gurnee, IL 60031, USA Ó Pharmaceutical Press 2010 is a trade mark of Pharmaceutical Press Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society of Great Britain First edition published 2006 Second edition published 2010 Typeset by Thomson Digital, Noida, India Printed in Great Britain by TJ International, Padstow, Cornwall ISBN 978 0 85369 912 5 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the prior written permission of the copyright holder. The publisher makes no representation, express or implied, with regard to the accuracy of the information contained in this book and cannot accept any legal responsibility or liability for any errors or omissions that may be made. The right of John F Marriott, Keith A Wilson, Christopher A Langley and Dawn Belcher to be identified as the author of this work has been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988. -
Topical Analgesics
Extra Evidence-basedBandolier health care March 2005 TOPICAL ANALGESICS: A REVIEW OF REVIEWS AND A BIT OF PERSPECTIVE Executive summary In chronic conditions in six trials with 429 patients topical This issue of Bandolier Extra pulls together the available salicylate was significantly better than placebo with an NNT evidence about topical analgesics. It covers analgesics that of 5.3 (CI 3.6 to 10.2), but the three larger, more valid studies are rubbed onto the skin to produce pain relief, and will were without significant effect. examine topical capsaicin, topical rubefacients and topical NSAIDs. It will not cover topical local anaesthetics. Local adverse events and withdrawals were generally rare in trials that reported them. The facts are important for payers and prescribers. But they are also important for consumers. Topical analgesics Topical NSAIDs are widely available without prescription, and widely advertised. Consumers need to have the best information Topical NSAIDs were well investigated in acute painful available, as well. The evidnece is that topical NSAIDs are conditions, which were all musculoskeletal in nature, in effective and safe. trials using one week outcomes. In this review, systematic reviews were sought for topical Topical NSAID was significantly better than placebo in 19 of capsaicin, rubefacients, and NSAIDs, in acute and chronic the 26 trials, with a pooled relative benefit of 1.6 (1.4 to 1.7), painful conditions. Reviews included only trials that were and NNT of 3.8 (3.4 to 4.4) compared with placebo for the randomised, double blind, had more than 10 patients in each outcome of half pain relief at seven days. -
(12) Patent Application Publication (10) Pub. No.: US 2003/0175333 A1 Shefer Et Al
US 2003.0175333A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0175333 A1 Shefer et al. (43) Pub. Date: Sep. 18, 2003 (54) INVISIBLE PATCH FOR THE CONTROLLED Publication Classification DELIVERY OF COSMETIC, DERMATOLOGICAL AND (51) Int. Cl." .......................... A61K 31/715; A61K 9/70 PHARMACEUTICALACTIVE INGREDIENTS (52) U.S. Cl. .............................................. 424/449; 514/61 ONTO THE SKN (76) Inventors: Adi Shefer, East Brunswick, NJ (US); (57) ABSTRACT Samuel Shefer, East Brunswick, NJ (US) The present invention relates to a patch for controlled topical Correspondence Address: or transdermal delivery of effective levels of cosmetic, Diane Dunn McKay dermatological, and pharmaceutical active ingredients onto Mathews, Collins, Shepherd & McKay, P.A. the skin, hair follicles, and Sebaceous glands, with minimal Suite 306 discomfort and ease of use. The patch can be transparent or 100 Thanet Circle clear and comprises a rate-controlling matrix layer. The matrix layer comprises water-Sensitive, bioadhesive, film Princeton, NJ 08540 (US) forming polymers, a water Soluble oligomer, and a Surfac (21) Appl. No.: 10/376,736 tant. The cosmetic, dermatological, and pharmaceutical active ingredients are Soluble or dispersed in the matrix. The (22) Filed: Feb. 28, 2003 patch becomes tacky when wetted and adheres onto the skin. The adhesive properties of the patch are Sufficient to main Related U.S. Application Data tain the patch in place on the skin for the recommended treatment period while allowing the patch to be readily (63) Continuation-in-part of application No. 10/091,935, removed without causing skin irritation or leaving adhesive filed on Mar. 6, 2002. -
Pharmacology for Dentistry
This page intentionally left blank Copyright © 2007, New Age International (P) Ltd., Publishers Published by New Age International (P) Ltd., Publishers All rights reserved. No part of this ebook may be reproduced in any form, by photostat, microfilm, xerography, or any other means, or incorporated into any information retrieval system, electronic or mechanical, without the written permission of the publisher. All inquiries should be emailed to [email protected] ISBN (13) : 978-81-224-2556-7 PUBLISHING FOR ONE WORLD NEW AGE INTERNATIONAL (P) LIMITED, PUBLISHERS 4835/24, Ansari Road, Daryaganj, New Delhi - 110002 Visit us at www.newagepublishers.com This page intentionally left blank PrefacePreface Pharmacology has undergone major intellectual changes in the recent years and has become increasingly important to all medical, dental and other health professionals. The graduate students of dentistry may have to handle medical emergency during various dental procedures on the dental chair. Besides this, dentists have to look into various drug associated interactions. The broad goal of teaching pharmacology to undergraduate students is to inculcate rational and scientific basis of therapeutics keeping in view the dental curriculum and profession. A sincere attempt has been made to present a complete text for undergraduate students of dentistry as per the new syllabus requirement (Dental Council of India, BDS course regulation, 2006). The book is divided into thirteen sections, initial sections cover the general and autonomic pharmacology, followed by other sections of drug acting on different body systems. A detailed section is devoted only to dental pharmacology which covers all agents used in pharmacotherapy of dental conditions. -
(12) United States Patent (10) Patent No.: US 7,858,570 B2 Hare (45) Date of Patent: Dec
US00785857OB2 (12) United States Patent (10) Patent No.: US 7,858,570 B2 Hare (45) Date of Patent: Dec. 28, 2010 (54) COMPOSITIONS AND METHODS FOR 5,607,980 A 3, 1997 McAtee et al. REMOVINGURUSHOLAND TREATING 5,643,572 A 7/1997 Byers THE RESULTING SKIN CONDITION 5,686,074 A * 1 1/1997 Stewart ...................... 424,736 5,753,245 A 5/1998 Fowler et al. 76 O O 5,767,109 A * 6/1998 Sanchez et al. ............... 514,58 (76) Inventor: year tariusSon La., 5,811,111 A 9/1998 McAtee et al. s 5,859,066 A 1/1999 Rosen 5.990,065. A 11, 1999 V tal. (*) Notice: Subject to any disclaimer, the term of this 6,022,565 A 2, 2000 XE e patent is extended or adjusted under 35 6,110,475 A 8, 2000 Toma et al. U.S.C. 154(b) by 654 days. 6,113,929 A 9, 2000 Karl 6,423,746 B1* 7/2002 Yarbrough et al. .......... 514,561 (21) Appl. No.: 11/930,098 6,667,026 B1 12/2003 Goldman et al. 7,001,622 B1 2/2006 Berndt (22) Filed: Oct. 31, 2007 7,008,963 B2 3/2006 Yarbrough 7,025,972 B2 4/2006 Beall (65) Prior Publication Data 7,144,173 B2 12/2006 Policicchio et al. 7,198.806 B2 4/2007 Berndt US 2008/O1 O7742 A1 May 8, 2008 7.351,474 B2 * 4/2008 Etzrodt et al. ............... 428/407 Related U.S. Application Data * cited by examiner (62) Division of application No. -
WO 2018/005695 Al O
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2018/005695 A l 0 4 January 2018 (04.01.2018) W ! P O PCT (51) International Patent Classification: (72) Inventors: BASTA, Steven; 590 Berkeley Avenue, Menlo A61K 31/4035 (2006.01) A61P 17/04 (2006.01) Park, CA 94025 (US). JOING, Mark; 936 Clara Drive, Pa A61K 45/06 (2006.01) lo Alto, CA 94303 (US). ZHANG, Xiaoming; 1089 Rem- sen Court, Sunnyvale, CA 94087 (US). KWON, Paul; 3349 (21) International Application Number: Deer Hollow Dr, Danville, CA 94506 (US). PCT/US20 17/039829 (74) Agent: SILVERMAN, Lisa, N.; Morrison & Foerster LLP, (22) International Filing Date: 755 Page Mill Road, Palo Alto, CA 94304-1018 (US). 28 June 2017 (28.06.2017) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/356,280 29 June 2016 (29.06.2016) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/356,291 29 June 2016 (29.06.2016) US KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 62/356,301 29 June 2016 (29.06.2016) us MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/356,294 29 June 2016 (29.06.2016) us OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/356,286 29 June 2016 (29.06.2016) us SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TH, TJ, TM, TN, 62/356,271 29 June 2016 (29.06.2016) us TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. -
Topical Agents for the Management of Musculoskeletal Pain Steven P
342 Journal of Pain and Symptom Management Vol. 33 No. 3 March 2007 Special Article Topical Agents for the Management of Musculoskeletal Pain Steven P. Stanos, DO Chronic Pain Care Center, Rehabilitation Institute of Chicago, and Department of Physical Medicine and Rehabilitation, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA Abstract The recent recognition of the magnitude of cardiovascular risk of both nonselective nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors, in addition to the persistent concerns about the use of opioids, has brought increased attention to nonsystemic, topical analgesics. These agents have a favorable safety profile and there is increasing evidence indicating their efficacy for a variety of pain disorders. The use of topical analgesics in the treatment of the most prevalent musculoskeletal pain syndromes is described, with a focus on mechanisms for drug delivery and clinical trials data. J Pain Symptom Manage 2007;33:342e355. Ó 2007 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. Key Words Counterirritants, local anesthetics, musculoskeletal pain, topical analgesics Introduction may provide a safe and effective therapeutic approach for some musculoskeletal pains. Musculoskeletal pain encompasses a wide spectrum of disorders from simple ligamen- tous injuries (e.g., ankle sprains) to intra- articular disorders (e.g., osteoarthritis and rheumatoid arthritis), muscle pain syndromes Epidemiology (e.g., myofascial pain and fibromyalgia), and Low back pain (LBP) and osteoarthritis are various spine-related neck and low back condi- the most common musculoskeletal disorders. tions (e.g., disc degeneration, disc herniation, LBP creates a significant burden on society facet arthropathies, and spondylosis). -
Common Clinical Conditions and Minor Ailments Common Clinical Conditions and Minor Ailments
COMMON CLINICAL CONDITIONS AND MINOR AILMENTS COMMON CLINICAL CONDITIONS AND MINOR AILMENTS CONTENTS ACKNOWLEDGEMENTS 3 1 ABOUT THIS PACKAGE 4 2 GASTRO-INTESTINAL SYSTEM 9 2.1 Dyspepsia 10 2.2 Gastro-oesophageal reflux disease (GORD) 14 2.3 Colic 17 2.4 Constipation 20 2.5 Diarrhoea 25 2.6 Irritable bowel syndrome 30 2.7 Haemorrhoids (piles) 32 Case studies 35 Suggested responses to gastro-intestinal activities 36 3 RESPIRATORY SYSTEM 39 3.1 Cough 40 3.2 Cold 46 3.3 Hayfever (seasonal allergic rhinitis) 50 Case studies 53 Suggested responses to respiratory activities 54 4 CENTRAL NERVOUS SYSTEM 57 4.1 Pain relief 58 4.2 Teething in children 61 4.3 Musculoskeletal pain – strains, sprains and bruises 62 4.4 Headache and migraine 66 4.5 Sleep problems 71 4.6 Travel sickness 73 Case studies 74 Suggested responses to central nervous system activities 75 5 INFECTIONS AND INFESTATIONS 77 5.1 Threadworm 78 5.2 Head lice 80 5.3 Scabies 84 5.4a Herpes simplex 87 5.4b Shingles 89 5.5 Fungal skin infections 92 5.5a Athlete’s foot 93 5.5b Fungal nail infections 96 5.5c Ringworm 98 5.5d Sweat rash 100 5.6 Impetigo 101 5.7 Other bacterial skin infections 103 5.8 Childhood infections 104 Case studies 105 Suggested responses to infection activities 106 1 NHS EDUCATION FOR SCOTLAND 6 OBSTETRICS, GYNAECOLOGY AND URINARY TRACT INFECTIONS 109 6.1 Lower urinary tract infection 110 6.2 Vaginal thrush (vulvovaginal candidiasis) 115 6.3 Vaginal dryness (atrophic vaginitis) 118 6.4 Dysmenorrhoea 120 Case studies 123 Suggested responses to obstetrics, gynaecology